NCT02303821 2025-06-04Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic LeukemiaAmgenPhase 1 Completed141 enrolled 37 charts
NCT03384654 2025-05-25A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaJanssen Research & Development, LLCPhase 2 Completed47 enrolled 22 charts
NCT02393859 2024-05-29Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Completed111 enrolled 23 charts 1 FDA
NCT04067518 2023-04-20A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic LeukemiaServierPhase 2 Completed28 enrolled 14 charts